Cargando…
Candidate genes associated with the effect of rosiglitazone on glycemic control and cardiovascular system in the treatment of type 2 diabetes mellitus
In the present study, candidate genes affected by rosiglitazone to exert glycemic control in the treatment of type 2 diabetes mellitus (T2DM) and associated with its adverse cardiovascular effects were identified using a bioinformatics analysis. The gene expression profiles of the dataset GSE36875 f...
Autor principal: | Wu, Xiaoli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364243/ https://www.ncbi.nlm.nih.gov/pubmed/30783475 http://dx.doi.org/10.3892/etm.2019.7160 |
Ejemplares similares
-
Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial
por: Florez, H, et al.
Publicado: (2015) -
Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications
por: Huri, Hasniza Zaman, et al.
Publicado: (2015) -
Transcriptome Alteration in the Diabetic Heart by Rosiglitazone: Implications for Cardiovascular Mortality
por: Wilson, Kitchener D., et al.
Publicado: (2008) -
Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus
por: Toi, Norikazu, et al.
Publicado: (2018) -
Effects of rosiglitazone on serum paraoxonase activity
and metabolic parameters in patients with type 2 diabetes
mellitus
por: Atamer, Y., et al.
Publicado: (2013)